Cantor Fitzgerald Predicts Belite Bio FY2026 Earnings

Belite Bio, Inc (NASDAQ:BLTE) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Belite Bio in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Kim forecasts that the company will post earnings per share of ($2.00) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share.

A number of other equities research analysts also recently weighed in on BLTE. Wall Street Zen downgraded Belite Bio from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Belite Bio in a research report on Thursday, May 15th. Finally, Benchmark restated a “buy” rating and set a $80.00 price target on shares of Belite Bio in a research report on Wednesday, March 26th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.67.

Belite Bio Stock Up 1.7%

NASDAQ BLTE opened at $62.14 on Wednesday. The stock’s 50-day simple moving average is $60.90 and its two-hundred day simple moving average is $61.16. Belite Bio has a twelve month low of $43.70 and a twelve month high of $86.53. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -55.98 and a beta of -1.44.

Belite Bio (NASDAQ:BLTE) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Belite Bio by 43.3% in the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company’s stock worth $122,000 after buying an additional 559 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Belite Bio in the fourth quarter worth about $155,000. XTX Topco Ltd increased its holdings in shares of Belite Bio by 30.9% in the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company’s stock worth $446,000 after buying an additional 1,668 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Belite Bio by 130.3% in the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company’s stock worth $924,000 after buying an additional 8,280 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Belite Bio by 36.4% in the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after buying an additional 4,891 shares during the period. Hedge funds and other institutional investors own 0.53% of the company’s stock.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.